IM156

ImmunoMet Therapeutics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	IM156
Sponsor	ImmunoMet Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. (PHASE1)
Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IM156 CI brief — competitive landscape report
IM156 updates RSS · CI watch RSS
ImmunoMet Therapeutics, Inc. portfolio CI